Review: Adult Outcome as Seen Through Controlled Prospective Follow-up Studies of Children With Attention-Deficit/Hyperactivity Disorder Followed Into Adulthood

Footnotes

These studies have been funded by major funding agencies such as the Canadian Medical Research Council (MRC), the National Institute of Mental Health (NIMH), and the National Institute on Drug Abuse (NIDA).

This article is part of a special series devoted to the subject of child and adolescent attention-deficit/hyperactivity disorder (ADHD). The series covers a range of topics in the area including genetics, neuroimaging, treatment, and others. The series was edited by Guest Editor Jonathan Posner, MD along with Deputy Editor Samuele Cortese, MD, PhD.

Author Contributions

Conceptualization: Roy, Hinshaw, Hechtman

Data curation: Molina, Weiss, Barkley, Biederman, Uchida, Owens, Hechtman

Formal analysis: Roy

Investigation: Molina, Weiss, Barkley, Biederman, Uchida, Hinshaw, Owens, Hechtman

Writing – original draft: Cherkasova, Roy, Molina, Scott, Barkley, Biederman, Uchida, Hinshaw, Owens, Hechtman

Writing – review and editing: Scott, Hechtman

The authors would like to acknowledge the contributions of all study participants, their parents/guardians, and the investigators. The authors wish to thank Rachel Klein, PhD, of the New York University Child Study Center, New York City, New York, for her pioneering work as a Co-PI of the New York follow-up study; Mariellen Fischer, PhD, of Associated Mental Health Consultants, Wauwatosa, Milwaukee, Wisconsin for her contribution as a Co-PI of the Milwaukee follow-up study; and William E. Pelham, Jr., PhD, of the Florida International University Center for Children and Families, Miami, Florida, for his origination of the Pittsburgh follow-up study and contributions as a Co-PI.

Disclosure: Dr. Cherkasova has received research funding from the Canadian Institutes of Health Research (CIHR) and the International Center for Responsible Gaming. She has received a speaker’s honorarium from the Responsible Gaming Association of New Mexico. Dr. Roy has held stocks in Pfizer Inc. and Viatris. Dr. Barkley has received royalties for books, a newsletter, and rating scales from Guilford Press and the American Psychological Association. He has received royalties for Internet CE courses from Premier Educational Seminars, Inc. and ContinuingEdCourses.net. He has received speaker fees from Medice Pharmaceutical Co. (Germany), Ironshore Pharmaceutical Development Co., and Takeda Pharmaceutical Co. Dr. Biederman has received research support from the American Academy of Child and Adolescent Psychiatry, the Feinstein Institute for Medical Research, Genentech, Headspace Inc., NIDA, Pfizer Pharmaceuticals, Roche TCRC Inc., Sunovion Pharmaceuticals Inc., Takeda/Shire Pharmaceuticals Inc., Tris, the Food and Drug Administration, Lundbeck AS, Neurocentria Inc., and the National Institutes of Health (NIH). He has received honoraria for a scientific presentation from Multi-Health Systems and a one-time consultation for Cowen Healthcare Investments, from MGH Psychiatry Academy for tuition-funded CME courses, for a scientific presentation from Tris and from the Institute of Integrated Sciences – INI (Brazil), and from Medlearning Inc., New York University, and MGH Psychiatry Academy for tuition-funded CME courses. His program have received royalties from a copyrighted rating scale used for ADHD diagnoses, paid by Biomarin, Bracket Global, Cogstate, Ingenix, Medavent Prophase, Shire, Sunovion, and Theravance; these royalties were paid to the Department of Psychiatry at MGH through Partners Healthcare Innovation. He has a partnership with MEMOTEXT to commercialize a digital health intervention to improve adherence in ADHD. Through MGH corporate licensing, he has a US Patent (#14/027,676) for a non-stimulant treatment for ADHD, a US Patent (#10,245,271 B2) on a treatment of impaired cognitive flexibility, and a patent pending (#61/233,686) on a method to prevent stimulant abuse. He has served as a consultant to Akili, Avekshan, Jazz Pharma, and Shire/Takeda. Through MGH CTNI, he has participated in a scientific advisory board for Supernus. Dr. Hinshaw has received research support from NIH and royalties for books published by Oxford University Press and St. Martin’s Press. Dr. Hechtman has served on the advisory board of, been a speaker for, and received research funding from Jansen, Shire, and Purdue. She has served on the advisory board for Ironshore. She has received research support from CIHR and the McGill Interdisciplinary Initiative in Infection and Immunity. She has received royalties for books published by John Hopkins University Press, Oxford University Press, the American Psychiatric Association, and Guilford Press. Drs. Molina, Weiss, Uchida, Owens and Ms. Scott have reported no biomedical financial interests or potential conflicts of interest.

留言 (0)

沒有登入
gif